



## Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

July 11, 2022

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- [Cue Biopharma, Inc.](#) (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body, announced today that it will take part in a fireside chat at the Guggenheim I&I Spotlight Series – Treg-based Therapies being held July 12–13, 2022.

### Presentation Details

#### Guggenheim I&I Spotlight Series – Treg-based Therapies

**Date and Time:** Wednesday, July 13 at 9:00 a.m.–9:45 a.m. EDT

**Webcast Link:** <https://kvgo.com/guggenheim/cue-biopharma-inc-july-2022>

A live and archived webcast of the presentation will be available on the Events page in the Investors and Media section of the Company's website at [www.cuebiopharma.com](http://www.cuebiopharma.com).

### About Cue Biopharma

Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body to transform the treatment of cancer. The company's proprietary Immuno-STAT™ (*Selective Targeting and Alteration of T cells*) platform, is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Boston, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information, visit <https://www.cuebiopharma.com> and follow us on Twitter at <https://twitter.com/CueBiopharma>.

### Investor Contact

Marie Campinell  
Senior Director, Corporate Communications  
Cue Biopharma, Inc.  
[mcampinell@cuebio.com](mailto:mcampinell@cuebio.com)

### Media Contact

Maya Romanchuk  
LifeSci Communications  
[mromanchuk@lifescicomms.com](mailto:mromanchuk@lifescicomms.com)



Source: Cue Biopharma, Inc.